# Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884

> **NCT03001297** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 64 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** MEDI5884 Dose 1
- **BIOLOGICAL:** MEDI5884 Dose 2
- **BIOLOGICAL:** MEDI5884 Dose 3
- **BIOLOGICAL:** MEDI5884 Dose 4

## Key facts

- **NCT ID:** NCT03001297
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-17
- **Primary completion:** 2018-08-10
- **Final completion:** 2018-08-10
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2018-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03001297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03001297, "Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03001297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*